Pharmaceutical - Pharmaceutical, Dermatologicals

Filter

Popular Filters

1 to 25 of 116 results

NICE seeks more information on Xolair to treat hives

19-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Swiss…

DermatologicalsNovartisPharmaceuticalPricingRegulationUKXolair

Leo Pharma reports positive results in its trial of Daivobet in psoriasis

Leo Pharma reports positive results in its trial of Daivobet in psoriasis

29-10-2014

Independent Danish dermatology specialist Leo Pharma has demonstrated significant improvement in psoriasis…

DaivobetDenmarkDermatologicalsLEO PharmaPharmaceuticalResearch

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

21-10-2014

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration…

DermatologicalsNovartisPharmaceuticalRegulationsecukinumabUSA

EADV: Celgene helps to raise awareness of psoriasis burden and presents new Otezla data

EADV: Celgene helps to raise awareness of psoriasis burden and presents new Otezla data

14-10-2014

US biotech company Celgene took a practical approach to raising awareness of psoriasis and psoriatic…

Celgene Corp.DermatologicalsEuropeHealthcareOtezlaPharmaceuticalResearchUSA

New Ph III data to support filing for AbbVie’s Humira in HS

13-10-2014

US pharma company AbbVie has reported new data with its mega blockbuster arthritis drug Humira (adalimumab)…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

Novartis' secukinumab shows strong efficacy in psoriasis Phase III trials

Novartis' secukinumab shows strong efficacy in psoriasis Phase III trials

10-10-2014

Swiss drug major Novartis has reported data from a Phase III trial showing consistent efficacy in clearing…

DermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Zynerba Pharmaceuticals announces CEO and president

Zynerba Pharmaceuticals announces CEO and president

02-10-2014

USA-based specialty pharmaceutical company Zynerba Pharmaceuticals, focused on innovative transdermal…

BoardroomDermatologicalsPharmaceuticalUSAZynerba Pharmaceuticals

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

25-09-2014

Swiss drug major Novartis' AIN457 (secukinumab) has met the primary and key secondary endpoints in two…

Anti-Arthritics/RheumaticsDermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Merck & Co out-licenses tildrakizumab to Sun Pharma

Merck & Co out-licenses tildrakizumab to Sun Pharma

17-09-2014

US pharma giant Merck & Co has entered into an exclusive worldwide licensing agreement with Indian drugmaker…

DermatologicalsGlobalLicensingMerck & CoPharmaceuticalSun Pharmaceuticalstildrakizumab

Positive new data for AbbVie’s Humira in HS

Positive new data for AbbVie’s Humira in HS

11-09-2014

US pharma group AbbVie has released results from a Phase III pivotal study demonstrating that its blockbuster…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

High long-term efficacy of LEO Pharma’s Picato in actinic keratosis confirmed

04-09-2014

New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers…

DermatologicalsLEO PharmaPharmaceuticalPicatoResearch

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

28-07-2014

The USA’s Retrophin has submitted an unsolicited $95 million takeover proposal to the board of directors…

AfamelanotideAustraliaClinuvel PharmaceuticalsDermatologicalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinScenesse

Ranbaxy to distribute Cipher’s isotretinoin product in Brazil

25-07-2014

Canada’s Cipher Pharmaceuticals has signed a definitive distribution and supply agreement with India’s…

BrazilCipher PharmaceuticalsDermatologicalsIsotretinoinLicensingPharmaceuticalRanbaxy Laboratories

Sandoz in deal to commercialize Anacor’s Kerydin in USA

Sandoz in deal to commercialize Anacor’s Kerydin in USA

22-07-2014

USA-based Anacor Pharmaceuticals has entered into an exclusive agreement with Sandoz, a subsidiary of…

Anacor PharmaceuticalsBusiness FinanceDermatologicalsKerydinLicensingMajorNovartisOnychomycosisPharmaceuticalPharmaceutical industryPharmaDermSandozTopical solutionUSA

LEO Pharma strikes global dermatology deal with KLOK Tech

LEO Pharma strikes global dermatology deal with KLOK Tech

16-07-2014

Danish dermatology specialist LEO Pharma and Canada’s KLOX Technologies, both privately-held companies,…

Acne vulgarisDermatologicalsGlobalKLOX TechnologiesLEO PharmaLicensingPharmaceutical

Stada Arz acquires Flexitol rights for UK and Ireland

Stada Arz acquires Flexitol rights for UK and Ireland

10-07-2014

Thornton & Ross, the UK subsidiary of German generic and branded drugmaker Stada Arzneimittel, has purchased…

DermatologicalsFlexitolIrelandMergers & AcquisitionsPharmaceuticalSTADA ArzneimittelThornton & RossUK

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

10-07-2014

Data published in the New England Journal of Medicine has shown secukinumab to be more effective at treating…

DermatologicalsetanerceptNovartisPharmaceuticalPsoriasisResearchsecukinumabUSA

FTC puts conditions on Valeant’s acquisition of Precision Dermatology

FTC puts conditions on Valeant’s acquisition of Precision Dermatology

04-07-2014

Canada’s Valeant Pharmaceuticals International and its takeover target Precision Dermatology have agreed…

ActavisDermatologicalsMatawan PharmaceuticalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyRegulationValeant Pharmaceuticals International

UCB and Dermira link up for Cimzia in dermatology

UCB and Dermira link up for Cimzia in dermatology

03-07-2014

Belgium’s largest drugmaker UCB and Dermira, a privately held USA-based dermatology company, have entered…

CanadaCimziaDermatologicalsDermiraEuropeLicensingPharmaceuticalResearchUCBUSA

US FDA grants Valeant approval for Jublia NDA

US FDA grants Valeant approval for Jublia NDA

09-06-2014

Canadian drugmaker Valeant Pharmaceuticals International’s US subsidiary has received approval from…

CanadaDermatologicalsefinaconazoleJubliaPharmaceuticalRegulationUS Food and Drug AdministrationValeant Pharmaceuticals

Positive Ph III results with Cubist’s Sivextro in ABSSSI

Positive Ph III results with Cubist’s Sivextro in ABSSSI

06-06-2014

USA-based Cubist Pharmaceutical saw its share rise 3.1% to $70.80 in morning trading Friday, after the…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDermatologicalsPharmaceuticalResearchSivextro

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

28-05-2014

US health care giant Johnson & Johnson subsidiary Janssen today received a negative opinion from UK watchdog…

DermatologicalsInflammatory diseasesJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelaraUK

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

28-05-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into an agreement to…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceuticalValeant Pharmaceuticals

1 to 25 of 116 results

Back to top